Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline
28 Nov 2022
Phase 1Phase 2
Preview
Source: FierceBiotech
Existing investor Sanofi Ventures came back for Escient's series C fundraise, throwing money in the pot to support the ultimate goal of creating new small molecule therapeutics.
Escient Pharmaceuticals has scored $120 million, a much heftier sum than its series B haul from a few years ago and once again snagging support from Big Pharma Sanofi’s VC arm.
The series C financing round was co-led by new investors New Enterprise Associates, Abingworth and Forge Life Science Partners, with existing investors Sanofi Ventures and 5AM Ventures in tow, among others.
The San Diego biotech’s fundraise follows a $77.5 million series B in September 2020, a round that occurred alongside Escient’s first in-human tests.
Now, the $120 million will help the biotech push forward investigational small molecule therapeutics for several neurosensory-inflammatory disorders, with a focus on lead candidates EP547 and EP262. The assets are designed to inhibit cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs, which mediate the neuro-immune overactivation associated with many chronic disorders.
By using small molecules to specifically block MRGPRX2 and MRGPRX4 activation, the company aims to develop oral medications for neurosensory-inflammatory diseases without the serious side effects tied to other approaches, Escient CEO Joshua Grass said in a Nov. 28 release. The $120 million financing will help the company advance its pipeline to clinical proof-of-concept in multiple indications.
EP547 targets MRGPRX4 with the aim of treating cholestatic and uremic pruritus, a form of severe itching resulting from liver or kidney disease. The asset is being evaluated in phase 2 and phase 1 trials, respectively, and Escient is exploring its potential in other unnamed indications.
EP262 is a MRGPRX2 antagonist in preclinical studies for chronic spontaneous urticaria, chronic inducible urticaria and atopic dermatitis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.